Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8,202,192 | 6,726,709 | 5,400,601 | 2,795,407 | 1,439,329 |
| Depreciation Amortization | 3,018,684 | 2,980,285 | 2,477,389 | 2,477,074 | 2,404,302 |
| Accounts receivable | -287,616 | -40,861 | -572,629 | -369,886 | -254,796 |
| Accounts payable and accrued liabilities | 288,900 | 335,825 | 174,859 | 14,177 | 130,109 |
| Other Working Capital | 3,150,936 | 453,300 | 4,651,778 | 2,299,219 | 5,432,042 |
| Other Operating Activity | -3,534,856 | -214,517 | -891,648 | 1,699,927 | -345,601 |
| Operating Cash Flow | $10,838,240 | $10,240,740 | $11,240,350 | $8,915,918 | $8,805,384 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 3,668,388 | -240,057 | -210,898 | -15,466 | 795,561 |
| PPE Investments | -1,486,872 | -1,493,973 | -1,569,725 | -1,629,043 | -1,958,408 |
| Net Acquisitions | 351,816 | -4,441,059 | 38,709 | 596,714 | 105,713 |
| Purchase Of Investment | -5,136 | N/A | -13,348 | N/A | N/A |
| Purchase Sale Intangibles | 310,728 | -630,789 | -261,621 | -784,879 | -712,888 |
| Other Investing Activity | 246,528 | -661,433 | -317,682 | -811,944 | -662,743 |
| Investing Cash Flow | $2,774,724 | $-6,836,522 | $-2,072,944 | $-1,859,738 | $-1,719,876 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -4,799,592 | 3,952,006 | 108,119 | N/A | 1,446,105 |
| Debt Issued | 4,234,632 | 6,121,458 | 13,532,200 | 2,877,890 | N/A |
| Common Stock Issued | 37,236 | 65,122 | 98,775 | 72,173 | 120,622 |
| Common Stock Repurchased | N/A | N/A | N/A | -83,772 | -100,292 |
| Dividend Paid | -5,106,468 | -5,047,586 | -5,241,760 | -5,034,053 | -6,573,205 |
| Other Financing Activity | -7,375,298 | -7,440,496 | -17,025,371 | -6,054,782 | -3,556,307 |
| Financing Cash Flow | $-13,009,490 | $-2,349,496 | $-8,528,037 | $-8,222,544 | $-8,663,077 |
| Exchange Rate Effect | -50,076 | -104,706 | 10,678 | -128,880 | 383,550 |
| Beginning Cash Position | 6,203,004 | 5,218,690 | 4,805,280 | 5,934,924 | 7,435,176 |
| End Cash Position | 6,756,408 | 6,168,704 | 5,455,328 | 4,639,680 | 6,241,157 |
| Net Cash Flow | $553,404 | $950,014 | $650,048 | $-1,295,244 | $-1,194,019 |
| Free Cash Flow | |||||
| Operating Cash Flow | 10,838,240 | 10,240,740 | 11,240,350 | 8,915,918 | 8,805,384 |
| Capital Expenditure | -1,574,184 | -1,615,278 | -1,793,971 | -1,991,196 | -2,091,228 |
| Free Cash Flow | 9,264,056 | 8,625,462 | 9,446,379 | 6,924,722 | 6,714,156 |